Form 8-K - Current report:
SEC Accession No. 0001193125-25-151276
Filing Date
2025-06-27
Accepted
2025-06-27 16:14:54
Documents
12
Period of Report
2025-06-26
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K d916678d8k.htm   iXBRL 8-K 38230
  Complete submission text file 0001193125-25-151276.txt   148958

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA fulc-20250626.xsd EX-101.SCH 2857
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE fulc-20250626_lab.xml EX-101.LAB 17236
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE fulc-20250626_pre.xml EX-101.PRE 10817
14 EXTRACTED XBRL INSTANCE DOCUMENT d916678d8k_htm.xml XML 3506
Mailing Address 26 LANDSDOWNE STREET CAMBRIDGE MA 02139
Business Address 26 LANDSDOWNE STREET CAMBRIDGE MA 02139 617-651-8851
Fulcrum Therapeutics, Inc. (Filer) CIK: 0001680581 (see all company filings)

EIN.: 474839948 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38978 | Film No.: 251086452
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)